Skip to main content
Premium Trial:

Request an Annual Quote

NIH To Award up to $3.8M in FY 2007 for Metabolomics-Based Pathway Research

NEW YORK, June 26 (GenomeWeb News) - The National Institutes of Health has set aside up to $3.8 million in funding for its 2007 fiscal year for projects that use metabolomics technologies in studying biological pathways.


In a request for applications released Friday and available here, NIH said that it will award between 7 and 10 projects under the program, called "Using Metabolomics to Investigate Biological Pathways and Networks."


The program "seeks to encourage the use of innovative metabolomics technologies to establish methods and model systems for advancing the understanding of biological pathways and networks; their temporal and spatial resolution; and their regulation in health and disease states," NIH said in the RFA.


Ideally, NIH said, "applications will study more complete views of pathways and networks defined by changes in metabolite concentrations including their sources, destinations, and activating or inhibiting feedback effects on pathway or network regulation."


Letters of intent are due Sept. 22 and applications are due Oct. 20.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.